Effektivnost' i bezopasnost' preparata Ekstimiya®, novogo pegilirovannogo filgrastima: rezul'taty otkrytogo sravnitel'nogo klinicheskogo issledovaniya II fazy patsientov s rakom molochnoy zhelezy, poluchayushchikh mielosupressivnuyu khimioterapiyu


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

The article is dedicated to the prevention and treatment of neutropenia associated with myelosuppressive chemotherapy in patients with malignant tumors, particularly breast cancer. For the prevention and treatment of neutropenia, recombinant drugs of human granulocyte colony stimulating factor are used for the last 20 years. The implementation of Extimia®, unique domestic drug of pegylated filgrastim (empegfilgrastim) in clinical practice would provide more available modern drug against neutropenia, with advantages over other pegylated filgrastim, for the target population of patients with cancer receiving myelosuppressive chemotherapy.

全文:

受限制的访问

参考

  1. Чиссов В.И., В.В. Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2011 году (заболеваемость и смертность). М., 2013.
  2. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. New Engi J Med 1991;325:164–70.
  3. Fishburn CS. The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. J Pharm Sci 2008;97(10):4167-83.
  4. Holmes FA, O'Shaughnessy JA, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 2002;20(3):727-31.
  5. Terashi К, Oka M, Ohdo S, et al. Close association between clearance of recombinant human granulocyte colony-stimulating factor (G-CSF) and G-CSF receptor on neutrophils in cancer patients. Antimicrob Agents Chemother 1999;43:21-4.
  6. Trillet-Lenoir V, Green J, Manegold С, et al. Recombinant granulocyte colony-stimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 1993;29A:319-24.
  7. Vogel CL, Wojtukiewicz MZ, Carroll RR, et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 2005;23(6):1178-84.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2013
##common.cookie##